Range Cancer Therapeutics ETF (CNCR) Short Interest Ratio & Short Volume

Short interest is the volume of Range Cancer Therapeutics ETF shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 24,600 shares of CNCR short. Learn More on Range Cancer Therapeutics ETF's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CNCR shares currently have a short interest ratio of 1.0. Learn More on Range Cancer Therapeutics ETF's short interest ratio.

Range Cancer Therapeutics ETF saw a increase in short interest in May. As of May 15th, there was short interest totaling 24,600 shares, an increase of 748.3% from the previous total of 2,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies compare to Range Cancer Therapeutics ETF: First Trust Nasdaq Pharmaceuticals ETF (0.13%), JPMorgan Healthcare Leaders ETF (0.08%), ProShares UltraShort Nasdaq Biotechnology (7.41%), Invesco Nasdaq Biotechnology ETF (0.71%), Principal Healthcare Innovators ETF (0.12%), ProShares Ultra Nasdaq Biotechnology (0.74%), Invesco S&P SmallCap Health Care ETF (0.03%), VanEck Biotech ETF (0.11%), VanEck Pharmaceutical ETF (19.53%), and iShares Biotechnology ETF (15.82%).

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling CNCR is an investing strategy that aims to generate trading profit from Range Cancer Therapeutics ETF as its price is falling. CNCR shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Range Cancer Therapeutics ETF occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CNCR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNCR, twice per month. The most recent reporting period available is May, 15 2024.